Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan;56(1):39-43.

Changes in blood pressure following escalating doses of phenylpropanolamine and a suggested protocol for monitoring

Gilad Segev  1 , Jodi L Westropp  1 , Chen Kulik  1 , Eran Lavy  1
Affiliations

Changes in blood pressure following escalating doses of phenylpropanolamine and a suggested protocol for monitoring

Gilad Segev et al. Can Vet J. 2015 Jan.

Abstract
in English, French

This prospective, cross-over, blinded study evaluated the effect of various doses of phenylpropanolamine (PPA) on blood pressure in dogs. Dogs were randomized to receive a placebo or 1 of 3 dosages of immediate release PPA, q12h for 7 days [1 mg/kg body weight (BW), 2 mg/kg BW, or 4 mg/kg BW] in a cross-over design. Blood pressure was recorded every 2 h, for 12 h, on days 1 and 7. There were significant increases in systolic, diastolic, and mean blood pressure following administration of PPA at 2 mg/kg BW and 4 mg/kg BW. A significant decrease in heart rate was also noted at all PPA dosages, but not in the placebo. Administration of PPA was associated with a dose response increase in blood pressure. Dosages of up to 2 mg/kg BW should be considered safe in healthy dogs.

Changements de la pression artérielle après des doses progressives de phénylpropanolamine et suggestion d’un protocole de surveillance. Cette étude prospective à l’insu et à plan d’étude croisée a évalué l’effet de diverses doses de phénylpropanolamine (PPA) sur la pression artérielle des chiens. Les chiens ont reçu au hasard un placebo ou 1 de 3 doses de PPA à action immédiate, q12h pendant 7 jours (1 mg/kg de poids corporel [PC], 2 mg/kg PC ou 4 mg/kg PC) dans un plan d’étude croisé. La pression artérielle a été consignée toutes les 2 h, pendant 12 h, aux jours 1 et 7. Il n’y a pas eu de hausses significatives de la pression artérielle systolique et diastolique ni de la pression artérielle moyenne après l’administration de PPA à 2 mg/kg PC et à 4 mg/kg PC. Une baisse significative de la fréquence cardiaque a aussi été notée dans toutes les doses de PPA, mais non avec le placebo. L’administration de PPA a été associée à une hausse de la pression artérielle en fonction de la dose. Des doses jusqu’à 2 mg/kg PC devraient être considérées sûres chez des chiens en santé.(Traduit par Isabelle Vallières).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes in systolic blood pressure over the 12 h following PPA administration in the 4 study groups: placebo group (Group 1), 1 mg/kg BW group (Group 2), 2 mg/kg BW group (Group 3), 4 mg/kg BW group (Group 4). The asterisks represent significant change compared to the baseline (prior to drug/placebo administration).
Figure 2
Figure 2
Changes in diastolic blood pressure over the 12 h following PPA administration in the 4 study groups: placebo group (Group 1), 1 mg/kg BW group (Group 2), 2 mg/kg BW group (Group 3), 4 mg/kg BW group (Group 4). The asterisks represent significant change compared to the baseline (prior to drug/placebo administration).
Figure 3
Figure 3
Changes in mean blood pressure over the 12 h following PPA administration in the 4 study groups: placebo group (Group 1), 1 mg/kg BW group (Group 2), 2 mg/kg BW group (Group 3), 4 mg/kg BW group (Group 4). The asterisks represent significant change compared to the baseline (prior to drug/placebo administration).
Figure 4
Figure 4
Changes in heart rate over the 12 h following PPA administration in the 4 study groups: placebo group (Group 1), 1 mg/kg BW group (Group 2), 2 mg/kg BW group (Group 3), 4 mg/kg BW group (Group 4). The asterisks represent significant change compared to the baseline (prior to drug/placebo administration).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Arnold S, Arnold P, Hubler M, Casal M, Rusch P. Urinary incontinence in spayed female dogs: Frequency and breed disposition. Schweizer Archiv fur Tierheilkunde. 1989;131:259–263. - PubMed
    1. Holt P. Urinary incontinence in the bitch due to sphincter mechanism incompetence: Prevalence in referred dogs and retrospective analysis of sixty cases. J Small Anim Pract. 1985;26:181–190.
    1. Janszen B, van Laar P, Bergman J. Treatment of urinary incontinence in the bitch: A pilot field study with Incurin1. Vet Q. 1997;19 sup1:42. - PubMed
    1. Mandigers RJ, Nell T. Treatment of bitches with acquired urinary incontinence with oestriol. Vet Rec. 2001;149:764–767. - PubMed
    1. Hamaide AJ, Verstegen JP, Snaps FR, Onclin KJ, Balligand MH. Influence of the estrous cycle on urodynamic and morphometric measurements of the lower portion of the urogenital tract in dogs. Am J Vet Res. 2005;66:1075–1083. - PubMed

MeSH terms

Substances